A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Status Not authorised · 2 EU/EEA countries · 2 sites · Protocol CUSP06-1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans

Status Not authorised

Participants planned 197

Countries 2

Sites 2

Platinum-resistant ovarian cancer (PROC)

Key facts

Sponsor: Oncusp Therapeutics Inc.
Participant type: Patients
Age range: 18-64 years, 65+ years
Gender: Male and Female
Therapeutic area: Diseases [C] - Neoplasms [C04]
Decision date (initial): 2025-06-18
Transition trial: No
Low-intervention: No
Rare-disease indication: No
Vulnerable population: Yes

External identifiers

EU CT number: 2024-519862-33-00
ClinicalTrials.gov: NCT06234423

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Platinum-resistant ovarian cancer (PROC)

Version	Level	Code	Term	System organ class
20.0	PT	10033128	Ovarian cancer	100000004864
25.0	LLT	10086821	Advanced renal cell carcinoma	100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Oncusp Therapeutics Inc.

Sponsor organisation: Oncusp Therapeutics Inc.
Address: 433 Broadway
City: New York
Postcode: 10013-2510
Country: United States

Scientific contact point

Organisation: Oncusp Therapeutics Inc.
Contact name: Priya Marreddy

Public contact point

Organisation: Oncusp Therapeutics Inc.
Contact name: Priya Marreddy

Locations

2 EU/EEA countries · 2 investigational sites

By country

Country	MS status	Planned subjects	Sites
Denmark	Not authorised	10	1
Spain	Not authorised	10	1
Rest of world United Kingdom, United States	—	177	—

Investigational sites

Denmark

1 site · Not authorised

Rigshospitalet

Department of Oncology, Blegdamsvej 9, 2100, Copenhagen Oe

Spain